Geode Capital Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-674,636
| Closed | -$116M | – | 5031 |
|
|
2021
Q3 | $116M | Buy |
674,636
+4,815
| +0.7% | +$630K | 0.02% | 712 |
|
|
2021
Q2 | $84.1M | Buy |
669,821
+14,645
| +2% | +$1.85M | 0.01% | 903 |
|
|
2021
Q1 | $88.8M | Buy |
655,176
+21,601
| +3% | +$2.79M | 0.01% | 823 |
|
|
2020
Q4 | $81.1M | Buy |
633,575
+40,826
| +7% | +$4.79M | 0.01% | 797 |
|
|
2020
Q3 | $66.7M | Buy |
592,749
+34,769
| +6% | +$3.46M | 0.01% | 778 |
|
|
2020
Q2 | $53.2M | Sell |
557,980
-124,865
| -18% | -$12M | 0.01% | 863 |
|
|
2020
Q1 | $61.4M | Buy |
682,845
+43,011
| +7% | +$3.34M | 0.02% | 667 |
|
|
2019
Q4 | $33.9M | Buy |
639,834
+24,423
| +4% | +$1.11M | 0.01% | 1201 |
|
|
2019
Q3 | $24.3M | Buy |
615,411
+16,593
| +3% | +$720K | 0.01% | 1341 |
|
|
2019
Q2 | $24.6M | Buy |
598,818
+57,536
| +11% | +$2.38M | 0.01% | 1343 |
|
|
2019
Q1 | $25.2M | Buy |
541,282
+87,819
| +19% | +$3.86M | 0.01% | 1265 |
|
|
2018
Q4 | $19.7M | Buy |
453,463
+32,521
| +8% | +$1.62M | 0.01% | 1283 |
|
|
2018
Q3 | $24.1M | Buy |
420,942
+20,967
| +5% | +$1.03M | 0.01% | 1270 |
|
|
2018
Q2 | $19.4M | Buy |
399,975
+34,637
| +9% | +$1.26M | 0.01% | 1376 |
|
|
2018
Q1 | $14.3M | Buy |
365,338
+14,906
| +4% | +$634K | ﹤0.01% | 1509 |
|
|
2017
Q4 | $14.9M | Buy |
350,432
+27,598
| +9% | +$1.04M | 0.01% | 1481 |
|
|
2017
Q3 | $12M | Buy |
322,834
+28,689
| +10% | +$996K | ﹤0.01% | 1591 |
|
|
2017
Q2 | $8.94M | Buy |
294,145
+22,705
| +8% | +$658K | ﹤0.01% | 1738 |
|
|
2017
Q1 | $7.18M | Buy |
271,440
+7,378
| +3% | +$194K | ﹤0.01% | 1850 |
|
|
2016
Q4 | $6.74M | Buy |
264,062
+3,680
| +1% | +$117K | ﹤0.01% | 1858 |
|
|
2016
Q3 | $9.42M | Buy |
260,382
+14,023
| +6% | +$465K | ﹤0.01% | 1538 |
|
|
2016
Q2 | $8.37M | Buy |
246,359
+9,131
| +4% | +$297K | ﹤0.01% | 1564 |
|
|
2016
Q1 | $6.26K | Buy |
237,228
+25,003
| +12% | +$727K | ﹤0.01% | 1725 |
|
|
2015
Q4 | $10.3M | Buy |
212,225
+12,481
| +6% | +$449K | 0.01% | 1359 |
|
|
2015
Q3 | $4.97M | Buy |
199,744
+122,144
| +157% | +$3.67M | ﹤0.01% | 1850 |
|
|
2015
Q2 | $2.46M | Buy |
77,600
+8,358
| +12% | +$270K | ﹤0.01% | 2368 |
|
|
2015
Q1 | $2.63M | Buy |
69,242
+1,891
| +3% | +$75.2K | ﹤0.01% | 2268 |
|
|
2014
Q4 | $2.62M | Buy |
67,351
+1,951
| +3% | +$68K | ﹤0.01% | 2254 |
|
|
2014
Q3 | $1.98M | Buy |
65,400
+8,346
| +15% | +$235K | ﹤0.01% | 2363 |
|
|
2014
Q2 | $1.94M | Buy |
57,054
+6,721
| +13% | +$225K | ﹤0.01% | 2383 |
|
|
2014
Q1 | $1.74M | Buy |
50,333
+17,212
| +52% | +$777K | ﹤0.01% | 2421 |
|
|
2013
Q4 | $1.31M | Buy |
+33,121
| New | +$799K | ﹤0.01% | 2549 |
|
Geode Capital Management's XLRN Position: Q4 2021 in Review
Geode Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 674,636 shares — an estimated $116M sold.
Geode Capital Management first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $116M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Geode Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Geode Capital Management sold 674,636 Acceleron Pharma shares in Q4 2021, an estimated $116M.
- Geode Capital Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Geode Capital Management's Acceleron Pharma position peaked at $116M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Geode Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.